Patient-derived models facilitate precision medicine in liver cancer by remodeling cell-matrix interaction

Frontiers in Immunology

Immunology

Yiying Tao¹  Xuehan Yan²  Bingran Wang³  Qiang Xia³  Kaiwen Chen³  Zhifeng Xi³  Kang He³  Yanran Li³  Weizhou Song⁴ 

[1] Department of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;Shanghai Engineering Research Center of Transplantation and Immunology, Shanghai, China;Shanghai Institute of Transplantation, Shanghai, China;Ottawa-Shanghai Joint School of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China;

关键词: patient derived models;    tumor models;    cell-matrix interaction;    liver cancer;    precision medicine;   

DOI  :  10.3389/fimmu.2023.1101324

 received in 2022-11-17, accepted in 2023-04-24,  发布年份 2023

来源: Frontiers

【 摘 要 】

Liver cancer is an aggressive tumor originating in the liver with a dismal prognosis. Current evidence suggests that liver cancer is the fifth most prevalent cancer worldwide and the second most deadly type of malignancy. Tumor heterogeneity accounts for the differences in drug responses among patients, emphasizing the importance of precision medicine. Patient-derived models of cancer are widely used preclinical models to study precision medicine since they preserve tumor heterogeneity ex vivo in the study of many cancers. Patient-derived models preserving cell-cell and cell-matrix interactions better recapitulate in vivo conditions, including patient-derived xenografts (PDXs), induced pluripotent stem cells (iPSCs), precision-cut liver slices (PCLSs), patient-derived organoids (PDOs), and patient-derived tumor spheroids (PDTSs). In this review, we provide a comprehensive overview of the different modalities used to establish preclinical models for precision medicine in liver cancer.

【 授权许可】

Unknown   
Copyright © 2023 Chen, Li, Wang, Yan, Tao, Song, Xi, He and Xia